InsiderTrades.com logo
“Generational Bull Run” Incoming
From Unstoppable Prosperity   |   Ad
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
You can find out what they are by clicking here now.

LXEO Insider Trading

Insider Ownership Percentage: 4.50%
Insider Buying (Last 12 Months): $4,999,995.00
Insider Selling (Last 12 Months): $444,988.50

Lexeo Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Lexeo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lexeo Therapeutics Share Price & Price History

Current Price: $11.50
Price Change: ▼ Price Decrease of -0.29 (-2.46%)
As of 07/26/2024 01:00 AM ET

This chart shows the closing price history over time for LXEO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks
From The Oxford Club   |   Ad
Usually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...
Click here now to claim your FREE copy of Marc's AI playbook.

Lexeo Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/10/2024Richard Nolan TownsendCEOSell26,969$16.50$444,988.50148,726View SEC Filing Icon  
11/7/2023Fund Vi L.P. OmegaMajor ShareholderBuy454,545$11.00$4,999,995.002,157,623View SEC Filing Icon  
See Full Table
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
From Paradigm Press   |   Ad
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Click here to see it because it’s a SHOCKER…

SEC Filings (Institutional Ownership Changes) for Lexeo Therapeutics (NASDAQ:LXEO)

60.67% of Lexeo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LXEO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Lexeo Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
7/26/2024Bank of New York Mellon Corp31,806$0.51M0.0%+12.3%0.097%Search for SEC Filing on Google Icon
5/17/2024RA Capital Management L.P.660,938$10.36M0.1%N/A2.006%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.801,716$12.57M0.3%+32.9%2.434%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC2,540,785$39.80M0.0%+9.0%7.713%Search for SEC Filing on Google Icon
5/14/2024American International Group Inc.5,053$79K0.0%N/A0.015%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.481,755$7.55M0.0%+15.8%1.462%Search for SEC Filing on Google Icon
5/1/2024BNP Paribas Financial Markets4,781$75K0.0%N/A0.015%Search for SEC Filing on Google Icon
4/29/2024Cornell University126,258$1.98M30.0%N/A0.383%Search for SEC Filing on Google Icon
2/20/2024Eventide Asset Management LLC3,002,831$40.30M0.7%N/A11.268%Search for SEC Filing on Google Icon
2/15/2024Omega Fund Management LLC2,157,623$28.96M23.5%N/A8.096%Search for SEC Filing on Google Icon
2/15/2024Blackstone Inc.696,110$9.34M0.0%N/A2.612%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Lexeo Therapeutics logo
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More on Lexeo Therapeutics

Today's Range

Now: $11.50
Low: $11.36
High: $12.05

50 Day Range

MA: $15.32
Low: $11.09
High: $18.76

52 Week Range

Now: $11.50
Low: $9.00
High: $22.33

Volume

299,534 shs

Average Volume

179,234 shs

Market Capitalization

$378.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Lexeo Therapeutics?

Lexeo Therapeutics' top insider investors include:
  1. Fund Vi LP Omega (Major Shareholder)
  2. Richard Nolan Townsend (CEO)
Learn More about top insider investors at Lexeo Therapeutics.

Who are the major institutional investors of Lexeo Therapeutics?

Lexeo Therapeutics' top institutional shareholders include:
  1. Bank of New York Mellon Corp — 0.10%
Learn More about top institutional investors of Lexeo Therapeutics stock.

Which institutional investors are buying Lexeo Therapeutics stock?

During the last quarter, LXEO stock was purchased by institutional investors including:
  1. Bank of New York Mellon Corp
“Generational Bull Run” Incoming
From Unstoppable Prosperity   |   Ad
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
You can find out what they are by clicking here now.